Cholinesterase inhibitors and beyond.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current Alzheimer Research

• Publication date

  2009-03-31

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.2174/156720509787602861PMID 19355843
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Non-cholinergic Effects of Huperzine A: Beyond Inhibition of Acetylcholinesterase

  2008cited by this paper
• Promising anti-Alzheimer's dimer bis(7)-tacrine reduces beta-amyloid generation by directly inhibiting BACE-1 activity.

  2008cited by this paper
• Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer’s disease

  2008cited by this paper
• Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: A clinical report series

  2007cited by this paper
• Nonmedical Influences on the Use of Cholinesterase Inhibitors in Dementia Care

  2007cited by this paper
• Add-on Therapy With Acetylcholinesterase Inhibitors for Memory Dysfunction in Schizophrenia: A Systematic Quantitative Review, Part 2

  2007cited by this paper
• Prescription patterns and efficacy of drugs for patients with dementia: physicians’ perspective in Italy

  2007cited by this paper
• Neurochemical and neurobehavioral effects of ganstigmine (CHF2819), a novel acetylcholinesterase inhibitor, in rat prefrontal cortex: an in vivo study.

  2007cited by this paper
• Cerebral acetylcholinesterase imaging: development of the radioprobes.

  2007cited by this paper
• N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine.

  2007cited by this paper
• Imaging treatment effects in Alzheimer's disease.

  2007cited by this paper
• Phenserine

  2007cited by this paper
• The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-β Peptide Levels in Cell Culture and Mice

  2007cited by this paper
• Anti-dementia drugs and hippocampal-dependent memory in rodents

  2007cited by this paper
• Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.

  2007cited by this paper
• Cholinesterase inhibitors reduce cortical Aβ in dementia with Lewy bodies

  2007cited by this paper
• Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors.

  2006cited by this paper
• Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer‐like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein

  2006cited by this paper
• Cholinesterase inhibitors for Alzheimer's disease.

  2006influential reference
• Comparison of Galantamine and Donepezil for Effects on Nerve Growth Factor, Cholinergic Markers, and Memory Performance in Aged Rats

  2006influential reference
• CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitor.

  2006cited by this paper
• Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer’s disease

  2006cited by this paper
• Donepezil in the treatment of narcolepsy.

  2006cited by this paper
• Neuroprotection via inhibition of nitric oxide synthase by bis(7)-tacrine

  2006cited by this paper
• Cholinesterases in human brain: the effect of cholinesterase inhibitors on Alzheimer's disease and related disorders

  2006cited by this paper
• Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies.

  2006cited by this paper
• Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease

  2006cited by this paper
• Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent.

  2005cited by this paper
• Effects on Cholinergic Markers in Rat Brain and Blood after Short and Prolonged Administration of Donepezil

  2005cited by this paper
• Indicators of neuroprotection with galantamine.

  2005cited by this paper
• Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients.

  2005cited by this paper
• Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.

  2005cited by this paper
• Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model

  2005cited by this paper
• Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.

  2005cited by this paper
• Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease

  2005cited by this paper
• Spatial discrimination deficits by excitotoxic lesions in the Morris water escape task.

  2005cited by this paper
• Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer’s disease

  2005cited by this paper
• Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: implications for Tourette's syndrome.

  2005cited by this paper
• Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent

  2005cited by this paper
• Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss.

  2004cited by this paper
• Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.

  2004cited by this paper
• Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-alpha in intracerebroventricular beta-amyloid-(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells.

  2004cited by this paper
• Acetylcholinesterase-Aβ Complexes Are More Toxic than Aβ Fibrils in Rat Hippocampus : Effect on Rat β-Amyloid Aggregation, Laminin Expression, Reactive Astrocytosis, and Neuronal Cell Loss

  2004cited by this paper
• Acetylcholinesterase inhibitors: novel activities of old molecules.

  2004cited by this paper
• Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats.

  2004cited by this paper
• Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.

  2003cited by this paper
• Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice

  2003cited by this paper
• A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease.

  2003cited by this paper
• Complementary and Alternative Medicines in the Treatment of Dementia

  2003cited by this paper
• Psychoactive Drugs and Pilot Performance: A Comparison of Nicotine, Donepezil, and Alcohol Effects

  2003cited by this paper
• Chronic treatments with tacrine and (−)-nicotine induce different changes of nicotinic and muscarinic acetylcholine receptors in the brain of aged rat

  2002cited by this paper
• Regional Effects of Donepezil and Rivastigmine on Cortical Acetylcholinesterase Activity in Alzheimer’s Disease

  2002cited by this paper
• Effects of Rivastigmine on Cognitive Function in Dementia with Lewy Bodies: A Randomised Placebo-Controlled International Study Using the Cognitive Drug Research Computerised Assessment System

  2002cited by this paper
• Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats

  2002cited by this paper
• Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid ß-protein

  2001cited by this paper
• Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment.

  2001cited by this paper
• A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation.

  2001cited by this paper
• Huperzine A attenuates cognitive deficits and hippocampal neuronal damage after transient global ischemia in gerbils.

  2001cited by this paper
• Effects of chronic metrifonate treatment on cholinergic enzymes and the blood-brain barrier.

  2001cited by this paper
• Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors.

  2000cited by this paper
• Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.

  2000cited by this paper
• Galantamine

  2000cited by this paper
• Bis(7)-tacrine, a promising anti-Alzheimer's agent, reduces hydrogen peroxide-induced injury in rat pheochromocytoma cells: comparison with tacrine.

  2000cited by this paper
• In vivo neurochemical effects of the acetylcholinesterase inhibitor ENA713 in rat hippocampus.

  2000influential reference
• A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066.

  1999cited by this paper
• Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students.

  1999cited by this paper
• The cholinergic hypothesis of Alzheimer’s disease: a review of progress

  1999cited by this paper
• Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students.

  1999cited by this paper
• Selectivity of Cholinesterase Inhibition

  1999cited by this paper
• Two-Year Treatment of Alzheimer’s Disease with Eptastigmine

  1999cited by this paper
• Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

  1999cited by this paper
• The acetylcholinesterase inhibitor, ENA 713 (Exelon), attenuates the working memory impairment induced by scopolamine in an operant DNMTP task in rats

  1999cited by this paper
• Metrifonate treatment of the cognitive deficits of Alzheimer's disease

  1998cited by this paper
• Effect of subchronic treatment with metrifonate and tacrine on brain cholinergic function in aged F344 rats.

  1998cited by this paper
• Cholinesterase Inhibitors Do More than Inhibit Cholinesterase

  1997cited by this paper
• Repeated administration of tacrine to normal rats: effects on cholinergic, glutamatergic, and GABAergic receptor subtypes in rat brain using receptor autoradiography.

  1997cited by this paper
• Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats.

  1997cited by this paper
• Ameliorating effects of SDZ ENA 713 on age-associated decreases in learning performance and brain choline acetyltransferase activity in rats.

  1997cited by this paper
• The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex.

  1996cited by this paper
• Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme.

  1996cited by this paper
• An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors.

  1996cited by this paper
• The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.

  1996cited by this paper
• The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial

  1996cited by this paper
• Cholinesterases and the pathology of Alzheimer disease.

  1995cited by this paper
• Second generation cholinesterase inhibitors: Effect of (L)‐huperzine‐A on cortical biogenic amines

  1995cited by this paper
• Physostigmine and galanthamine: probes for a novel binding site on the alpha 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells.

  1994cited by this paper
• Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia

  1994cited by this paper
• Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors.

  1994cited by this paper
• Tetrahydroaminoacridine and Alzheimer's disease

  1994cited by this paper
• Cholinesterase inhibitor effects on extracellular acetylcholine in rat striatum.

  1993cited by this paper
• Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex.

  1993cited by this paper
• Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability

  1993cited by this paper
• Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography.

  1992cited by this paper
• Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors.

  1992cited by this paper
• E2020 - THE PHARMACOLOGY OF A PIPERIDINE CHOLINESTERASE INHIBITOR

  1991cited by this paper
• Tetrahydroaminoacridine induces opposite changes in muscarinic and nicotinic receptors in rat brain.

  1990cited by this paper
• Nootropic drugs and brain cholinergic mechanisms

  1989cited by this paper
• Current Research in Alzheimer Therapy

  1989cited by this paper
• A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice.

  1988cited by this paper
• Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

  1986cited by this paper

• Low toxicity ferrocene-1,2,3-Triazole hybrids as acetylcholinesterase and butyrylcholinesterase inhibitors: Synthesis, antioxidant activity, enzyme inhibition, cytotoxicity properties and molecular docking studies.

  2025cites this paper
• Non-neuronal cholinergic stimulation favors bone mass accrual

  2025cites this paper
• Chemical Composition, Antioxidant, and Enzyme Inhibitory Activities of Onosma bulbotrichum Extracts

  2025cites this paper
• Recent advances in bioisosteric modifications for targeting Alzheimer's disease pathways.

  2025cites this paper
• A multi enzyme study reviewing the role of target enzymes in Alzheimer’s disease and unveiling potential inhibitors with insights on their present and future assessment

  2025cites this paper
• Molecular recognition and potentiometric determination of neostigmine and pyridostigmine by a methylene-bridged naphthotube

  2025cites this paper
• Design, synthesis, in silico, and in vitro evaluation of pyrrol-2-yl-phenyl allylidene hydrazine carboximidamide derivatives as AChE/BACE 1 dual inhibitors

  2024cites this paper
• Porphyrin Schiff bases as potential Alzheimer's disease drug candidates: Synthesis, in silico and DFT studies

  2024cites this paper
• Innovative Therapeutic Strategies in Alzheimer’s Disease: A Synergistic Approach to Neurodegenerative Disorders

  2024cites this paper
• Exploring avenues for Alzheimer’s drugs: current status and future outlook

  2024cites this paper
• The risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors: a meta-analysis

  2024cites this paper
• Synthesis and evaluation of potential multitargeted ligands based on chromene analogs for suppressing lysozyme amyloid aggregation

  2024cites this paper
• Long-Term Acetylcholinesterase Depletion Alters the Levels of Key Synaptic Proteins while Maintaining Neuronal Markers in the Aging Zebrafish (Danio rerio) Brain

  2023cites this paper
• Sexually Dimorphic Effects of Neuromodulatory Drugs on Normal and Stress-Induced Social Interaction in Rats

  2023cites this paper
• Identification of Potent and Selective Acetylcholinesterase/Butyrylcholinesterase Inhibitors by Virtual Screening

  2023cites this paper
• Drug Candidates for the Treatment of Alzheimer’s Disease: New Findings from 2021 and 2022

  2023cites this paper
• No genetic causal association between Alzheimer’s disease and osteoporosis: A bidirectional two-sample Mendelian randomization study

  2023cites this paper
• Benzofuran Hybrids as Cholinesterase (AChE and BChE) Inhibitors: In Vitro, In Silico, and Kinetic Studies

  2022cites this paper
• Design, synthesis and SAR studies of novel tacrine derivatives as potent cholinesterase inhibitors

  2022cites this paper
• Cholinergic stimulation of fracture healing: An animal study

  2022cites this paper
• Pharmacological targeting of cognitive impairment in depression: recent developments and challenges in human clinical research

  2022cites this paper
• Novel benzofurane carbonyl analogs of donepezil as acetylcholinesterase inhibitors

  2022cites this paper
• Novel coumarin derivatives as multifunctional anti-AD agents: Design, synthesis, X-ray crystal structure and biological evaluation

  2022cites this paper
• Promising heterocycle-based scaffolds in recent (2019-2021) anti-Alzheimer's drug design and discovery.

  2022cites this paper
• AChE as a Spark in the Alzheimer's Blaze - Antagonizing Effect of a Cyclized Variant.

  2022cites this paper
• Drug Discovery in CNS: Finding a Target for What?

  2021cites this paper
• Synthesis, bioactivity and binding energy calculations of novel 3-ethoxysalicylaldehyde based thiosemicarbazone derivatives.

  2020cites this paper
• Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.

  2020cites this paper
• Design, synthesis and biological evaluation of novel carboline-cinnamic acid hybrids as multifunctional agents for treatment of Alzheimer's disease.

  2020cites this paper
• Neuroprotective Role of Dietary Supplementation with Omega-3 Fatty Acids in the Presence of Basal Forebrain Cholinergic Neurons Degeneration in Aged Mice

  2020cites this paper
• Behavioral, neuromorphological, and neurobiochemical effects induced by omega-3 fatty acids following basal forebrain cholinergic depletion in aged mice

  2020cites this paper
• Cholinergic Signaling Dynamics and Cognitive Control of Attention.

  2020cites this paper
• Re‐pigmentation of hair after prolonged cholinesterase inhibitor therapy in a Chinese population

  2020cites this paper
• Recent Advances in the Synthesis and Biological Activity of 8-Hydroxyquinolines

  2020cites this paper
• Phosphonamidate Compounds for Butyrylcholinesterase Selective Inhibitors

  2020cites this paper
• A Unique GSK-3β inhibitor B10 Has a Direct Effect on Aβ, Targets Tau and Metal Dyshomeostasis, and Promotes Neuronal Neurite Outgrowth

  2020cites this paper
• Nicotine Neuroprotection of Brain Neurons: The Other Side of Nicotine Addiction

  2019cites this paper
• Ethoxylated Head of Chalcones as a New Class of Multi‐Targeted MAO Inhibitors

  2019cites this paper
• Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.

  2019cites this paper
• Resveratrol and Its Analogues: Recent Advances in Structural Modification and Bioactivity.

  2019cites this paper
• Translational investigations of the intersection between Alzheimer’s disease and epilepsy: mechanistic insights and treatment opportunities

  2019cites this paper
• Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease

  2019cites this paper
• Development of novel carbazole derivatives with effective multifunctional action against Alzheimer's diseases: Design, synthesis, in silico, in vitro and in vivo investigation.

  2019cites this paper
• Novel chromanone-dithiocarbamate hybrids as multifunctional AChE inhibitors with β-amyloid anti-aggregation properties for the treatment of Alzheimer's disease.

  2019cites this paper
• Design, synthesis and evaluation of quinolinone derivatives containing dithiocarbamate moiety as multifunctional AChE inhibitors for the treatment of Alzheimer’s disease

  2019cites this paper
• Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer's disease.

  2019cites this paper
• Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.

  2019cites this paper
• Cholinesterase Inhibition Activity and Docking Simulation Study of Coumarin Mannich Base Derivatives

  2019cites this paper
• 35 Highly Sensitive Method for Analysis Anticholinesterase Drugs

  2019cites this paper
• Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids.

  2019cites this paper
• Design, synthesis and anti-Alzheimer's disease activity study of xanthone derivatives based on multi-target strategy.

  2019cites this paper
• Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).

  2019cites this paper
• Preparation of 4-Flexible Amino-2-Arylethenyl-Quinoline Derivatives as Multi-Target Agents for the Treatment of Alzheimer’s Disease

  2018cites this paper
• Acetylcholinesterase inhibitors and the risk of osteoporotic fractures: nested case-control study

  2018cites this paper
• New advances in pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors

  2018cites this paper
• Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.

  2018cites this paper
• Evaluation of the rivastigmine role against botulinum toxin-A-induced osteoporosis in albino rats: A biochemical, histological, and immunohistochemical study

  2018cites this paper
• Discovery of boron-containing compounds as Aβ aggregation inhibitors and antioxidants for the treatment of Alzheimer's disease.

  2018cites this paper
• Donepezil Improves Histological and Biochemical Changes in the Hippocampus of Adult Hypothyroid Male Rats

  2018cites this paper
• PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment

  2018cites this paper
• Design, synthesis, in-silico and biological evaluation of novel donepezil derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.

  2017cites this paper
• Design, Synthesis, and Biological Evaluation of a New Series of Biphenyl/Bibenzyl Derivatives Functioning as Dual Inhibitors of Acetylcholinesterase and Butyrylcholinesterase

  2017cites this paper
• Co-modulation of an allosteric modulator of nicotinic receptor-cholinesterase inhibitor (galantamine) and a 5-HT4 receptor agonist (RS-67333): effect on scopolamine-induced memory deficit in the mouse

  2017cites this paper
• Effects of Cholinesterase Inhibitors Tacrine and Galantamine in Pentilentetrazole induced Cognitive Dysfunction in Mice

  2017cites this paper
• DL0410 Ameliorates Memory and Cognitive Impairments Induced by Scopolamine via Increasing Cholinergic Neurotransmission in Mice

  2017cites this paper
• Synthesis and biological evaluation of deferiprone-resveratrol hybrids as antioxidants, Aβ1-42 aggregation inhibitors and metal-chelating agents for Alzheimer's disease.

  2017cites this paper
• Microcephaly associated with Zika virus infection – prevention, diagnosis and treatment

  2017cites this paper
• Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.

  2017cites this paper
• Concurrent administration of thyroxine and donepezil induces plastic changes in the prefrontal cortex of adult hypothyroid rats

  2017cites this paper
• Rivastigmine patch reduces the incidence of postoperative delirium in older patients with cognitive impairment

  2017cites this paper
• Natural Plant‐Derived Acetylcholinesterase Inhibitors: Relevance for Alzheimer's Disease

  2017cites this paper
• Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation.

  2017cites this paper
• Coumarin derivatives bearing benzoheterocycle moiety: synthesis, cholinesterase inhibitory, and docking simulation study

  2017cites this paper
• Identification of 2-subsituted benzothiazole derivatives as triple-functional agents with potential for AD therapy

  2016cites this paper
• NGF and BDNF Gene Therapy for Alzheimer’s Disease

  2016cites this paper
• A novel acetylcholinesterase inhibitor and calcium channel blocker SCR-1693 improves Aβ25–35-impaired mouse cognitive function

  2016cites this paper
• The dual-acting AChE inhibitor and H3 receptor antagonist UW-MD-72 reverses amnesia induced by scopolamine or dizocilpine in passive avoidance paradigm in rats.

  2016cites this paper
• The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats.

  2016cites this paper
• Synthesis and evaluation of 8-hydroxyquinolin derivatives substituted with (benzo[d][1,2]selenazol-3(2H)-one) as effective inhibitor of metal-induced Aβ aggregation and antioxidant.

  2016cites this paper
• Anti-amyloid Aggregation Activity of Natural Compounds: Implications for Alzheimer’s Drug Discovery

  2016cites this paper
• Quantitative analysis of neuropathological alterations in two transgenic mouse models of Alzheimer's disease

  2016cites this paper
• Donepezil regulates energy metabolism and favors bone mass accrual.

  2016cites this paper
• Design, synthesis and evaluation of novel indandione derivatives as multifunctional agents with cholinesterase inhibition, anti-β-amyloid aggregation, antioxidant and neuroprotection properties against Alzheimer's disease.

  2016cites this paper
• Design, synthesis and cholinesterase inhibitory evaluation study of fluorescent N-benzylpiperidine-4-one derivatives

  2016cites this paper
• Synthesis and evaluation of neuroprotective 4-O-substituted chrysotoxine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease

  2016cites this paper
• Design, synthesis and evaluation of clioquinol–ebselen hybrids as multi-target-directed ligands against Alzheimer's disease

  2016cites this paper
• Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation.

  2016cites this paper
• Solanocapsine derivatives as potential inhibitors of acetylcholinesterase: Synthesis, molecular docking and biological studies.

  2015cites this paper
• Galantamine protects against lipopolysaccharide-induced acute lung injury in rats

  2015cites this paper
• Tibetan medicine "RNSP" in treatment of Alzheimer disease.

  2015cites this paper
• Discovery of butyrylcholinesterase inhibitors among derivatives of azaphenothiazines

  2015cites this paper
• Aging Mechanisms

  2015cites this paper
• Implication des recepteurs nicotiniques α7 dans les deficits mnesiques induits par des injections intra-hippocampiques de peptides amyloïdes-beta (1-42) chez la souris

  2015cites this paper
• Review Article Tibetan medicine "RNSP" in treatment of Alzheimer disease

  2015cites this paper
• Gene Therapy for Alzheimer’s Disease

  2015cites this paper
• New multifunctional melatonin-derived benzylpyridinium bromides with potent cholinergic, antioxidant, and neuroprotective properties as innovative drugs for Alzheimer's disease.

  2015cites this paper
• Knowledge of Signal Transduction Provides an Approach to Attacking Memory Decline

  2015cites this paper
• Dysfunctional Presynaptic M2 Receptors in the Presence of Chronically High Acetylcholine Levels: Data from the PRiMA Knockout Mouse

  2015cites this paper
• Design, synthesis and evaluation of chromone-2-carboxamido-alkylbenzylamines as multifunctional agents for the treatment of Alzheimer's disease.

  2015cites this paper
• Design of a structural framework with potential use to develop balanced multifunctional agents against Alzheimer's disease

  2015cites this paper